CT-guided high-dose-rate brachytherapy of metachronous ovarian cancer metastasis to the liver: initial experience.

Autor:	Collettini F; Charité, Campus Mitte, Charitelatz 1, 10117 Berlin, Germany. federico.collettini@charite.de, Poellinger A, Schnapauff D, Denecke T, Wust P, Braicu IE, Sehouli J, Hamm B, Gebauer B
Jazyk:	angličtina
Zdroj:	Anticancer research [Anticancer Res] 2011 Aug; Vol. 31 (8), pp. 2597-602.
Abstrakt:	Aim: Hepatic resection for hepatic ovarian cancer metastases remains controversial. The purpose of this study was to evaluate the clinical outcome of CT-guided high dose rate brachytherapy (CT-HDRBT) for minimally invasive cytoreduction of isolated metachronous ovarian cancer metastases to the liver. Patients and Methods: Seven patients with 12 isolated ovarian cancer metastases to the liver were treated with CT-HDRBT. To evaluate tumor response a gadolinium ethoxybenzyl diethylenetriaminepentaacetic acid (Gd-EOB-DTPA)-enhanced liver MRI was performed before, six weeks after and every third month after treatment. Results: The mean MRI-follow-up period was 15.4 months. Tumors ranged from 13 to 120 mm in diameter. Complete ablation was achieved for all lesions. No complications occurred. No local progression was observed in any of the included patients. Overall survival was 100% after 12 months. Two patients died after 14 and 25 months, respectively. Conclusion: CT-HDRBT is a safe and valid technique for performing minimally invasive cytoreduction of metachronous isolated liver metastases from ovarian cancer.
Databáze:	MEDLINE
Externí odkaz:	Zobrazit plný text záznamu